Single‐Nuclei RNA Sequencing Shows the Engagement of PPAR‐Delta Target Genes Primarily in Hepatocytes and Cholangiocytes by the Selective PPAR‐Delta Agonist Seladelpar

Résumé fourni par la source

Background and Aims The selective peroxisome proliferator–activated receptor delta (PPARD) agonist seladelpar reduces liver injury and modulates bile acid metabolism in preclinical models. Seladelpar was recently approved for the secondary treatment of primary biliary cholangitis (PBC). Despite its beneficial effects for liver diseases, the target cells of seladelpar on a single‐cell level remain unknown. This study is aimed at investigating the effect of seladelpar on single liver cells. Methods and Results CD‐1 mice were gavaged with vehicle or seladelpar (10 mg/kg body weight), and the liver was harvested 6 h later. Single‐nuclei RNA sequencing (snRNA‐seq) analysis showed the engagement of PPARD target genes primarily in hepatocytes and cholangiocytes by seladelpar. The top two upregulated genes, Ehhadh and Cyp4a14 , are related to fatty acid metabolism and were increased in hepatocytes, cholangiocytes, and Kupffer cells. Abcb4 , an important canalicular transporter with hepatoprotective effects, was significantly upregulated in hepatocytes. We confirmed upregulated Abcb4 gene expression in seladelpar‐treated primary mouse hepatocytes isolated from C57BL/6 mice. We further incubated nonparenchymal liver cells with seladelpar. Although there was a significant increase in the PPARD‐responsive genes Pdk4 and Angptl4 in cholangiocytes, Kupffer cells, and hepatic stellate cells, seladelpar did not exert specific liver‐protective effects in these cell types. Conclusion The selective PPARD agonist seladelpar induced PPARD‐responsive genes primarily in hepatocytes and cholangiocytes. Seladelpar upregulated Abcb4 in hepatocytes, which might contribute to its beneficial effects in cholestatic liver disorders.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.